Kronos Bio, Inc. Form 8-K: Current report
Filings on SEC EDGAR, newest first; amendments sit with their base form. Values are as filed.
- 2025-06-20: Form 8-K; Period of report 2025-06-20; Description 2.01 Completion of Acquisition or Disposition of Assets; 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing; 3.03 Material Modification to Rights of Security Holders; 5.01 Changes in Control of Registrant; 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers; 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year; Details 2.01.
- 2025-06-05: Form 8-K; Period of report 2025-06-04; Description 1.02 Termination of a Material Definitive Agreement; 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant; Details 1.02.
- 2025-05-01: Form 8-K; Period of report 2025-05-01; Description 1.01 Entry into a Material Definitive Agreement; 7.01 Regulation FD Disclosure; Details 1.01.
- 2025-04-10: Form 8-K; Period of report 2025-04-08; Description 1.02 Termination of a Material Definitive Agreement; Details 1.02.
| Filed | Form | Period of report | Description | Details | Document |
|---|---|---|---|---|---|
| 2025-06-20 | 8-K | 2025-06-20 | 2.01 Completion of Acquisition or Disposition of Assets; 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing; 3.03 Material Modification to Rights of Security Holders; 5.01 Changes in Control of Registrant; 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers; 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year | 2.01 As previously disclosed by Kronos Bio, Inc. (the “Company” or “Kronos”) in the Company’s Current Report on Form 8-K filed with the Securities and Exchange Commission (the “SEC”) on May 1, 2025, the Company entered into an Agreement and Plan of Merger, dated as of May 1, 2025 (the “Merger Agreement”) with Concentra Biosciences, LLC, a Delaware limited liability company (“Concentra”), and Concentra Merger Sub IV, Inc., a Delaware corporation and a wholly owned subsidiary of Concentra (“Merger Sub”). 3.01 The information set forth under Item 2.01 of this Current Report on Form 8-K is incorporated herein by reference into this Item 3.01. 3.03 The information set forth under Items 2.01, 3.01, 5.01 and 5.03 of this Current Report on Form 8-K is incorporated by reference into this Item 3.03. 5.01 The information set forth under Items 2.01, 5.02 and 5.03 of this Current Report on Form 8-K is incorporated by reference into this Item 5.01. 5.02 Pursuant to the terms of the Merger Agreement, at the Effective Time, each of Arie Belldegrun, M.D., Norbert Bischofberger, Ph.D., Roshawn Blunt, Roger Dansey, M.D., Joshua Kazam, Elena Ridloff, CFA, Katherine Vega Stultz, David M. Tanen and Taiyin Yang, Ph.D. resigned from the board of directors of the Company and Dr. Deborah Knobelman resigned from her position as an officer of the Company. 5.03 Pursuant to the terms of the Merger Agreement, at the Effective Time, the Company’s certificate of incorporation and bylaws were amended and restated in their entirety, as set forth on Exhibits 3.1 and 3.2, respectively, to this Current Report on Form 8-K and are incorporated herein by reference. | ea0246047-8k_kronos.htm |
| 2025-06-05 | 8-K | 2025-06-04 | 1.02 Termination of a Material Definitive Agreement; 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant | 1.02 On June 4, 2025, Kronos Bio, Inc. (the “Company”) entered into a Lease Termination Agreement (the “Termination Agreement”) with BMR-Rogers Street LLC, a Delaware limited liability company (the “Landlord”), pursuant to which the Company and the Landlord agreed to terminate that certain Office Lease, dated February 28, 2020, as amended (the “Original Lease”), related to the Company’s office and laboratory space located at 301 Binney Street, Cambridge, Massachusetts. 2.03 The information included in Item 1.02 included in this Current Report is hereby incorporated into this Item 2.03 by reference. | ea0244752-8k_kronos.htm |
| 2025-05-01 | 8-K | 2025-05-01 | 1.01 Entry into a Material Definitive Agreement; 7.01 Regulation FD Disclosure | 1.01 Entry into a Material Definitive Agreement. 7.01 On May 1, 2025, the Company issued a press release announcing the signing of the Merger Agreement, a copy of which is attached hereto as Exhibit 99.1 and incorporated by reference herein. | ea0240182-8k_kronos.htm |
| 2025-04-10 | 8-K | 2025-04-08 | 1.02 Termination of a Material Definitive Agreement | 1.02 On April 8, 2025, Kronos Bio, Inc. (the “Company”) entered into a Lease Termination Agreement (the “Termination Agreement”) with MPVCA San Mateo LLC, a California limited liability company (the “Landlord”), pursuant to which the Company and the Landlord agreed to terminate that certain Office Lease, dated July 19, 2018, as amended (the “Original Lease”), related to the Company’s corporate headquarters located at 1300 South El Camino Real, Suite 400, San Mateo, California. | kron-20250408.htm |
| 2025-03-18 | 8-K | 2025-03-18 | 2.02 Results of Operations and Financial Condition | 2.02 On March 18, 2025, Kronos Bio, Inc. (the “Company”) issued a press release announcing its financial results for the fourth quarter and year ended December 31, 2024. | kron-20250318.htm |
| 2024-12-27 | 8-K | 2024-12-20 | 1.02 Termination of a Material Definitive Agreement | 1.02 On December 20, 2024, Kronos Bio, Inc. (the “Company”) entered into a Transition Agreement and Mutual General Release (the “Transition Agreement”) with Genentech, Inc. and F. Hoffmann-La Roche Ltd (together, “Genentech”), pursuant to which the Company and Genentech agreed to void and cancel all of the parties’ respective rights and obligations under the Collaboration and License Agreement between the parties dated January 6, 2023 (the “Collaboration Agreement”). | kron-20241220.htm |
| 2024-11-27 | 8-K | 2024-11-22 | 2.05 Costs Associated with Exit or Disposal Activities; 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 2.05 On November 22, 2024, the Board of Directors (the “Board”) of Kronos Bio, Inc. (the “Company”) approved an approximately 83% reduction in its workforce as part of a strategic resource allocation and cost containment plan. 5.02 On November 22, 2024, Norbert Bischofberger, Ph.D., resigned as the Company’s President and Chief Executive Officer, effective December 3, 2024. | kron-20241122.htm |
| 2024-11-13 | 8-K | 2024-11-13 | 2.02 Results of Operations and Financial Condition | 2.02 On November 13, 2024, Kronos Bio, Inc. issued a press release providing a corporate update and announcing its financial results for the quarter ended September 30, 2024. | kron-20241113.htm |
| 2024-11-07 | 8-K | 2024-11-04 | 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing | 3.01 On November 4, 2024, Kronos Bio, Inc. (the “Company”) received a notice from The Nasdaq Stock Market (“Nasdaq”) that the Company is not in compliance with Nasdaq’s Listing Rule 5450(a)(1), as the minimum bid price of the Company’s common stock has been below $1.00 per share for 30 consecutive business days. | kron-20241104.htm |
| 2024-08-08 | 8-K | 2024-08-08 | 2.02 Results of Operations and Financial Condition | 2.02 On August 8, 2024, Kronos Bio, Inc. issued a press release providing a corporate update and announcing its financial results for the quarter ended June 30, 2024. | kron-20240808.htm |
| 2024-06-27 | 8-K | 2024-06-25 | 5.07 Submission of Matters to a Vote of Security Holders | 5.07 On June 25, 2024, Kronos Bio, Inc. (the “Company”) held its 2024 Annual Meeting of Stockholders (the “Annual Meeting”). | ef20031807_8k.htm |
| 2024-05-21 | 8-K | 2024-05-20 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 On May 20, 2024, the board of directors of Kronos Bio, Inc. (the “Company”) appointed Deborah Knobelman, Ph.D. as the Chief Financial Officer, principal financial officer and principal accounting officer of the Company, replacing Sandra Gardiner in such capacities, and as the Company’s Chief Operations Officer, with such appointments to be effective on June 3, 2024. | ef20029602_8k.htm |
| 2024-05-09 | 8-K | 2024-05-09 | 2.02 Results of Operations and Financial Condition | 2.02 On May 9, 2024, Kronos Bio, Inc. issued a press release providing a corporate update and announcing its financial results for the quarter ended March 31, 2024. | kron-20240509.htm |
| 2024-03-21 | 8-K | 2024-03-21 | 2.02 Results of Operations and Financial Condition | 2.02 On March 21, 2024, Kronos Bio, Inc. (the “Company”) issued a press release providing a corporate update and announcing its financial results for the fourth quarter and year ended December 31, 2023. | kron-20240321.htm |
| 2024-03-07 | 8-K | 2024-03-05 | 2.05 Costs Associated with Exit or Disposal Activities; 7.01 Regulation FD Disclosure | 2.05 On March 5, 2024, the Board of Directors of Kronos Bio, Inc. (the “Company”) approved an approximately 21% reduction in its workforce as part of a strategic resource allocation and cost containment plan. 7.01 As a result of the strategic resource allocation and cost containment plan referenced under Item 2.05 above, the Company expects that its existing resources will be sufficient to support the Company’s planned operations into the second half of 2026. | ef20023567_8k.htm |
| 2024-03-05 | 8-K | 2024-03-05 | 8.01 Other Events | 8.01 Kronos Bio, Inc. (the “Company”) is announcing that it has amended its protocol for its clinical trial of KB-0742, an oral CDK9 inhibitor in a phase 1/2 dose escalation and expansion trial in solid tumors. | ef20023134_8k.htm |
| 2024-01-25 | 8-K | 2024-01-24 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers; 8.01 Other Events | 5.02 On January 24, 2024, Kronos Bio, Inc. (the “Company”) and Jorge DiMartino, M.D., Ph.D., the Company’s Chief Medical Officer and Executive Vice President, Clinical Development, mutually agreed to the termination of Dr. DiMartino’s employment with the Company, effective February 16, 2024 (the “Separation Date”). 8.01 On January 24, 2024, the Company and Christopher Dinsmore, Ph.D., Chief Scientific Officer, mutually agreed to the termination of Dr. Dinsmore’s employment with the Company, effective the Separation Date. | ef20019756_8k.htm |
| 2023-12-19 | 8-K | 2023-12-18 | 8.01 Other Events | 8.01 On December 18, 2023, Kronos Bio, Inc. (the “Company”) announced an update on its pipeline. | ef20016865_8k.htm |
| 2023-11-13 | 8-K | 2023-11-13 | 2.02 Results of Operations and Financial Condition | 2.02 On November 13, 2023, Kronos Bio, Inc. issued a press release providing a corporate update and announcing its financial results for the quarter ended September 30, 2023. | kron-20231113.htm |
| 2023-11-02 | 8-K | 2023-10-30 | 2.05 Costs Associated with Exit or Disposal Activities; 7.01 Regulation FD Disclosure | 2.05 On October 30, 2023, the Board of Directors of Kronos Bio, Inc. (the “Company”) approved an approximately 19% reduction of its workforce as part of a strategic resource allocation, restructuring and cost containment plan. 7.01 As a result of the strategic resource allocation, restructuring and cost containment plan referenced under Item 2.05 above, the Company expects that its existing resources will be sufficient to support the Company’s planned operations into 2026. | ef20013915_8k.htm |
| 2023-10-05 | 8-K | 2023-10-05 | 7.01 Regulation FD Disclosure | 7.01 Kronos Bio, Inc. (the “Company”) is furnishing as Exhibit 99.1 to this report an abstract titled “A First-In-Human Study of CDK9 Inhibitor KB-0742 Demonstrates Evidence of Tolerability and Clinical Activity.” As previously announced, the Company will discuss the information in the abstract at the American Association for Cancer Research, National Cancer Institute and European Organisation for Research and Treatment of Cancer (AACR/NCI/EORTC) 2023 International Conference in Boston, MA on Friday, October 13, 2023. | ef20012007_8k.htm |
| 2023-09-18 | 8-K | 2023-09-14 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 On September 14, 2023, the Board of Directors of Kronos Bio, Inc. (the “Company”) appointed Sandra A. Gardiner as the Company’s interim Chief Financial Officer, as well as the Company’s principal financial officer and principal accounting officer, effective at the close of business on September 15, 2023. | ef20010826_8k.htm |
| 2023-08-17 | 8-K | 2023-08-14 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 On August 14, 2023, Yasir Al-Wakeel, BM BCh, the Chief Financial Officer and Head of Corporate Development, principal financial officer and principal accounting officer of Kronos Bio, Inc. (the “Company”), notified the Company of his decision to resign, effective at the close of business on September 15, 2023, to pursue other opportunities. | brhc20057606_8k.htm |
| 2023-08-08 | 8-K | 2023-08-08 | 2.02 Results of Operations and Financial Condition | 2.02 On August 8, 2023, Kronos Bio, Inc. issued a press release providing a corporate update and announcing its financial results for the quarter ended June 30, 2023. | kron-20230808.htm |
| 2023-06-26 | 8-K | 2023-06-22 | 5.07 Submission of Matters to a Vote of Security Holders | kron-20230622.htm | |
| 2023-05-30 | 8-K/A | 2023-04-07 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 On April 7, 2023, we appointed Katherine Vega Stultz to our Board of Directors (the “Board”) as a Class II director with a term ending at our annual meeting of stockholders to be held in 2025. | kron-20230407.htm |
| 2023-05-30 | 8-K/A | 2023-04-20 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 On April 20, 2023, we appointed Roger Dansey, M.D. to our Board of Directors (the “Board”) as a Class I director with a term ending at our annual meeting of stockholders to be held in 2024. | kron-20230420.htm |
| 2023-05-10 | 8-K | 2023-05-10 | 2.02 Results of Operations and Financial Condition | 2.02 On May 10, 2023, Kronos Bio, Inc. issued a press release providing a corporate update and announcing its financial results for the quarter ended March 31, 2023. | kron-20230510.htm |
| 2023-04-24 | 8-K | 2023-04-20 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 On April 20, 2023, we appointed Roger Dansey, M.D. to our Board of Directors (the “Board”) as a Class I director with a term ending at our annual meeting of stockholders to be held in 2024. | kron-20230420.htm |
| 2023-04-11 | 8-K | 2023-04-07 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 On April 7, 2023, we appointed Katherine Vega Stultz to our Board of Directors (the “Board”) as a Class II director with a term ending at our annual meeting of stockholders to be held in 2025. | kron-20230407.htm |
| 2023-03-27 | 8-K | 2023-03-22 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 On March 22, 2023, Otello Stampacchia, Ph.D., notified us of his decision to resign from our board of directors, effective March 31, 2023. | kron-20230322.htm |
| 2023-03-27 | 8-K/A | 2023-01-21 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 On January 21, 2023, Marianne De Backer, Ph.D., notified us of her decision to resign from our board of directors as a result of her recent appointment as Chief Executive Officer of Vir Biotechnology, Inc., and in consideration of her additional time commitments associated with such position, as well as the “overboarding” policies of shareholder advisory firms. | kron-20230121.htm |
| 2023-03-15 | 8-K | 2023-03-15 | 2.02 Results of Operations and Financial Condition | 2.02 On March 15, 2023, Kronos Bio, Inc. (the “Company”) issued a press release providing a corporate update and announcing its financial results for the fourth quarter and year ended December 31, 2022. | kron-20230315.htm |
| 2023-01-26 | 8-K | 2023-01-21 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 On January 21, 2023, Marianne De Backer, Ph.D., notified us of her decision to resign from our board of directors as a result of her recent appointment as Chief Executive Officer of Vir Biotechnology, Inc., and in consideration of her additional time commitments associated with such position, as well as the “overboarding” policies of shareholder advisory firms. | kron-20230121.htm |
| 2023-01-09 | 8-K | 2023-01-06 | 1.01 Entry into a Material Definitive Agreement; 7.01 Regulation FD Disclosure | 1.01 Entry into a Material Definitive Agreement. 7.01 After taking into account the Company’s receipt of the $20.0 million upfront payment described above, the Company anticipates that it will have sufficient resources to fund its planned operations into the second half of 2025. | kron-20230106.htm |
| 2022-11-08 | 8-K | 2022-11-08 | 2.02 Results of Operations and Financial Condition | 2.02 On November 8, 2022, Kronos Bio, Inc. issued a press release providing a corporate update and announcing its financial results for the quarter ended September 30, 2022. | kronos093020228kearnings.htm |
| 2022-08-04 | 8-K | 2022-06-30 | 2.02 Results of Operations and Financial Condition | 2.02 On August 4, 2022, Kronos Bio, Inc. issued a press release providing a corporate update and announcing its financial results for the quarter ended June 30, 2022. | kronos063020228kearnings.htm |
| 2022-06-23 | 8-K | 2022-06-22 | 5.07 Submission of Matters to a Vote of Security Holders | kron-20220622.htm | |
| 2022-05-04 | 8-K | 2022-05-04 | 2.02 Results of Operations and Financial Condition | 2.02 On May 4, 2022, Kronos Bio, Inc. issued a press release providing a corporate update and announcing its financial results for the quarter ended March 31, 2022. | kron-20220504.htm |
| 2022-04-21 | 8-K | 2022-04-20 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 On April 20, 2022, the Compensation Committee of the Board of Directors of Kronos Bio, Inc. (the “Company”) adopted the Kronos Bio, Inc. Severance and Change in Control Plan (the “Plan”). | kron-20220420.htm |
| 2022-02-24 | 8-K | 2022-02-24 | 2.02 Results of Operations and Financial Condition | 2.02 On February 24, 2022, Kronos Bio, Inc. (the “Company”) issued a press release providing a corporate update and announcing its financial results for the fourth quarter and year ended December 31, 2021. | kron-20220224.htm |
| 2021-12-06 | 8-K | 2021-12-06 | 8.01 Other Events | 8.01 On December 6, 2021, Kronos Bio, Inc. (the “Company”) announced that the first patient has been dosed in the registrational Phase 3 AGILITY clinical trial of entospletinib, a selective inhibitor targeting spleen tyrosine kinase (“SYK”), in combination with standard of care anthracycline and cytarabine (7+3) chemotherapy. | kron-20211206.htm |
| 2021-11-29 | 8-K | 2021-11-29 | 8.01 Other Events | 8.01 On November 29, 2021, Kronos Bio, Inc. (the “Company”) announced positive data from the ongoing Phase 1/2 clinical trial of KB-0742, the Company’s internally discovered, highly selective, oral cyclin dependent kinase 9 (“CDK9”) inhibitor being developed to treat MYC-amplified solid tumors. | kron-20211129.htm |
| 2021-11-12 | 8-K/A | 2021-11-11 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 On November 11, 2021, we appointed Roshawn Blunt to our Board of Directors (the “Board”) as a Class II director with a term ending at our annual meeting of stockholders to be held in 2022. | kron-20211111.htm |
| 2021-11-12 | 8-K | 2021-11-12 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 On November 11, 2021, we appointed Roshawn Blunt to our Board of Directors (the “Board”) as a Class II director with a term ending at our annual meeting of stockholders to be held in 2022. | kronos111121roshawnbluntbo.htm |
| 2021-11-09 | 8-K | 2021-11-09 | 2.02 Results of Operations and Financial Condition | 2.02 On November 9, 2021, Kronos Bio, Inc. issued a press release providing a corporate update and announcing its financial results for the quarter ended September 30, 2021. | kron-20211109.htm |
| 2021-08-12 | 8-K | 2021-08-12 | 2.02 Results of Operations and Financial Condition | 2.02 On August 12, 2021, Kronos Bio, Inc. issued a press release providing a corporate update and announcing its financial results for the quarter ended June 30, 2021. | kron-20210812.htm |
| 2021-06-25 | 8-K/A | 2021-06-22 | 5.07 Submission of Matters to a Vote of Security Holders | 5.07 On June 22, 2021, Kronos Bio, Inc. (the “Company”) held its 2021 Annual Meeting of Stockholders (the “Annual Meeting”). | kron-20210622.htm |
| 2021-06-24 | 8-K | 2021-06-23 | 5.07 Submission of Matters to a Vote of Security Holders | 5.07 On June 22, 2021, Kronos Bio, Inc. (the “Company”) held its 2021 Annual Meeting of Stockholders (the “Annual Meeting”). | kron-20210623.htm |
| 2021-05-25 | 8-K | 2021-05-25 | 8.01 Other Events | 8.01 On May 25, 2021, Kronos Bio, Inc. issued a press release titled “Kronos Bio to Highlight Progress Across Pipeline and Outline Growth Strategy at Virtual R&D Day Today.” A copy of the press release is included as Exhibit 99.1 to this Report on Form 8-K and incorporated by reference herein. | f8k_052521.htm |
| 2021-05-11 | 8-K | 2021-05-11 | 2.02 Results of Operations and Financial Condition | 2.02 On May 11, 2021, Kronos Bio, Inc. issued a press release providing a corporate update and announcing its financial results for the quarter ended March 31, 2021. | kron-20210511.htm |
| 2021-03-26 | 8-K | 2021-03-25 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 On March 25, 2021, we appointed Taiyin Yang, Ph.D., to our Board of Directors (the “Board”) as a Class I director with a term ending at our annual meeting of stockholders to be held in 2021. | f8k_032521.htm |
| 2021-03-23 | 8-K | 2021-03-23 | 2.02 Results of Operations and Financial Condition | 2.02 On March 23, 2021, Kronos Bio, Inc. (the “Company”) issued a press release providing a corporate update and announcing its financial results for the fourth quarter and year ended December 31, 2020. | kronos123120208kearnings.htm |
| 2021-03-04 | 8-K | 2021-03-04 | 8.01 Other Events | 8.01 On March 4, 2021, Kronos Bio, Inc. (the “Company”) announced, following receipt of minutes from the Company’s End-of-Phase 2 meeting with the U.S. Food and Drug Administration, that the Company will proceed with its plan to assess measurable residual disease (“MRD”) negative complete response (“CR”) as the primary endpoint in a registrational Phase 3 trial to support potential accelerated approval of entospletinib in patients newly diagnosed with NPM1-mutated acute myeloid leukemia. | f8k_030421.htm |
| 2021-02-10 | 8-K | 2021-02-08 | 1.01 Entry into a Material Definitive Agreement | 1.01 Entry into a Material Definitive Agreement. | f8k_021021.htm |
| 2021-01-26 | 8-K | 2021-01-26 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 On January 25, 2021, we appointed Marianne De Backer, Ph.D., to our Board of Directors (the “Board”) as a Class I director with a term ending at our annual meeting of stockholders to be held in 2021. | f8k_012621.htm |
| 2020-12-07 | 8-K | 2020-12-07 | 8.01 Other Events | 8.01 On December 7, 2020, we announced U.S. Food and Drug Administration clearance of our Investigational New Drug application for KB-0742, a highly selective, orally bioavailable inhibitor of cyclin dependent kinase 9 (CDK9). | f8k_120720.htm |
| 2020-11-18 | 8-K | 2020-11-18 | 2.02 Results of Operations and Financial Condition | 2.02 On November 18, 2020, Kronos Bio, Inc. announced its financial results for the quarter ended September 30, 2020. | kronos09302020earnings.htm |
| 2020-10-14 | 8-K | 2020-10-14 | 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year; 8.01 Other Events | 5.03 In connection with the closing of the initial public offering of shares of common stock (the “IPO”) of Kronos Bio, Inc. (the “Company”) on October 14, 2020, the Company filed an Amended and Restated Certificate of Incorporation (the “Restated Certificate”) with the Secretary of State of the State of Delaware. 8.01 On October 14, 2020, the Company issued a press release announcing the closing of the IPO of 15,131,579 shares of its common stock, including 1,973,684 shares issued and sold pursuant to the exercise in full by the underwriters of their option to purchase additional shares of common stock, at a price to the public of $19.00 per share. | kronos-closing8xk.htm |